Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CHKA | P35790 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6475097 | 0.84 | CHRM2 (0.58) | CHRM2MEN1KMT2ACHRM4CHRM5 | |
| SCHEMBL24400970 | 0.81 | MAPT (0.57) | TAAR1MAPTALDH1A1IDO1 | |
| SCHEMBL4499814 | 0.81 | ALDH1A1 (0.47) | CHRM2MEN1KMT2ACHRM4CHRM5 | |
| SCHEMBL8973436 | 0.79 | ALDH1A1 (0.46) | CHRM2MEN1KMT2ACHRM4CHRM5 | |
| SCHEMBL11288839 | 0.76 | CYP1A2 (0.68) | MEN1KMT2ACYP1A2CYP2A6TAAR1 | |
| SCHEMBL143961 | 0.76 | CYP1A2 (0.68) | MEN1KMT2ACYP1A2CYP2A6TAAR1 | |
| SCHEMBL3723023 | 0.73 | — | — | |
| SCHEMBL8973362 | 0.73 | CHRM2 (0.52) | CHRM2MEN1KMT2ACHRM4CHRM5 | |
| SCHEMBL21762340 | 0.72 | MAPT (0.41) | CHRM2MEN1KMT2ACHRM4CHRM5 | |
| SCHEMBL11839445 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220475-B2 | Monomers from biomass | NDSU RESEARCH FOUNDATION (US) | 2022-01-11 | — | — | US | disclosed |
| US-20210198175-A9 | NOVEL MONOMERS FROM BIOMASS | NDSU RESEARCH FOUNDATION (US) | 2021-07-01 | — | — | US | disclosed |
| US-20200140368-A1 | NOVEL MONOMERS FROM BIOMASS | NDSU RESEARCH FOUNDATION (US) | 2020-05-07 | — | — | US | disclosed |
| US-20180093939-A9 | NOVEL MONOMERS FROM BIOMASS | NDSU RESEARCH FOUNDATION (US) | 2018-04-05 | — | — | US | disclosed |
| US-9738753-B2 | Programmed degradation of polymers derived from biomass | NDSU RESEARCH FOUNDATION (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170233325-A1 | NOVEL MONOMERS FROM BIOMASS | NDSU RESEARCH FOUNDATION (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198175-A9 | NOVEL MONOMERS FROM BIOMASS | DCXR, MANBA, PGLS | CHRM2 3439/4885MEN1 3775/4885KMT2A 4022/4885 |
| US-20180093939-A9 | NOVEL MONOMERS FROM BIOMASS | DCXR, MANBA, PGLS | CHRM2 3439/4885MEN1 3775/4885KMT2A 4022/4885 |
| US-20170233325-A1 | NOVEL MONOMERS FROM BIOMASS | DCXR, MANBA, PGLS | CHRM2 3439/4885MEN1 3775/4885KMT2A 4022/4885 |
| US-20200140368-A1 | NOVEL MONOMERS FROM BIOMASS | DCXR, MANBA, PGLS | CHRM2 3439/4885MEN1 3775/4885KMT2A 4022/4885 |
| US-11220475-B2 | Monomers from biomass | DCXR, MGAM, ALG1 | CHRM2 3559/4885MEN1 2052/4885KMT2A 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.